Rapport Therapeutics' RAP-219 Shows Significant Seizure Reduction in Epilepsy Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
Should l Buy RAPP?
Source: NASDAQ.COM
- Significant Clinical Efficacy: Rapport Therapeutics' RAP-219 achieved a 90% median reduction in seizures during the first four weeks of follow-up after an eight-week treatment, indicating its clinical significance and potential market value in treating epilepsy.
- Robust Study Results: In a study involving 30 adults with drug-resistant focal onset seizures, RAP-219's long half-life of approximately 22 days allowed for a 90% median reduction in seizures during weeks 9-12 post-treatment, with a sustained 59% reduction in weeks 13-16, demonstrating its ability to maintain seizure control.
- Good Safety Profile: RAP-219 was generally well tolerated with only mild treatment-related side effects reported; serious adverse events occurred but were deemed unrelated to the drug by investigators, enhancing its feasibility for clinical use.
- Future Development Plans: Rapport plans to initiate two pivotal Phase 3 trials, FOCUS 1 and FOCUS 2, in the second quarter of 2026 to further evaluate RAP-219 for focal onset seizures, while also conducting a Phase 2 trial for bipolar mania, showcasing the company's broad strategy in neurological disorders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RAPP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RAPP
Wall Street analysts forecast RAPP stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.930
Low
40.00
Averages
54.60
High
80.00
Current: 39.930
Low
40.00
Averages
54.60
High
80.00
About RAPP
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rapport Therapeutics Q1 Financial Results Analysis
- Financial Performance: Rapport Therapeutics reported a Q1 GAAP EPS of -$0.42 with revenue of only $0.02 million, indicating significant challenges in revenue growth that may impact investor confidence.
- Cash Position: As of March 31, 2026, the company had $476.8 million in cash, cash equivalents, and short-term investments, down from $490.5 million as of December 31, 2025, reflecting pressure on the company's financial management.
- Cash Runway: The company expects its current cash and short-term investments to fund operating expenses and capital expenditures into the second half of 2029, although it faces challenges with low revenue, necessitating careful monitoring of cash utilization.
- Market Outlook: Rapport Therapeutics' presentation at the Stifel 2026 Virtual CNS Forum could influence its future financing capabilities, prompting investors to closely watch its subsequent financial performance and market reactions.
See More
Third Rock Ventures Sells Shares in Rapport Therapeutics
- Transaction Overview: Third Rock Ventures V, L.P. sold 426,005 shares of Rapport Therapeutics in an open-market transaction valued at approximately $17.18 million, reducing its ownership stake by 5.3% while still holding 6.7 million shares directly, indicating continued confidence in the company's prospects.
- Transaction Context: The sale was executed under a Rule 10b5-1 trading plan, suggesting it was a pre-scheduled liquidity event rather than discretionary selling, reflecting the management's strategic planning and market timing.
- Market Performance Impact: Following a 230% increase in Rapport Therapeutics' stock price over the past year, this divestment does not alter Third Rock's fundamental view on the company but rather appears to be a strategy to realize some gains while maintaining significant exposure to future growth.
- R&D Progress and Outlook: Rapport recently reported a 90% median reduction in clinical seizures for its RAP-219 Phase 2 trial, establishing a solid foundation for future drug development, with two Phase 3 trials expected to commence in the second quarter, further enhancing the company's growth potential.
See More
Rapport Therapeutics' RAP-219 Shows Significant Seizure Reduction in Epilepsy Patients
- Significant Clinical Efficacy: Rapport Therapeutics' RAP-219 achieved a 90% median reduction in seizures during the first four weeks of follow-up after an eight-week treatment, indicating its clinical significance and potential market value in treating epilepsy.
- Robust Study Results: In a study involving 30 adults with drug-resistant focal onset seizures, RAP-219's long half-life of approximately 22 days allowed for a 90% median reduction in seizures during weeks 9-12 post-treatment, with a sustained 59% reduction in weeks 13-16, demonstrating its ability to maintain seizure control.
- Good Safety Profile: RAP-219 was generally well tolerated with only mild treatment-related side effects reported; serious adverse events occurred but were deemed unrelated to the drug by investigators, enhancing its feasibility for clinical use.
- Future Development Plans: Rapport plans to initiate two pivotal Phase 3 trials, FOCUS 1 and FOCUS 2, in the second quarter of 2026 to further evaluate RAP-219 for focal onset seizures, while also conducting a Phase 2 trial for bipolar mania, showcasing the company's broad strategy in neurological disorders.
See More
Form 144: Rapport Therapeutics (RAPP.US) 10% Stakeholder Plans to Sell $17.18 Million in Common Shares
- Stock Sale Announcement: Third Rock Ventures, L.P. plans to sell 426,001 shares of its common stock on April 17, 2023.
- Market Value: The total market value of the shares being sold is approximately $17.18 million.
See More
Rapport Therapeutics Reports Q4 Earnings Miss
- Earnings Miss: Rapport Therapeutics reported a Q4 GAAP EPS of -$0.72, missing expectations by $0.03, indicating challenges in profitability that could impact investor confidence.
- Cash Position: The company ended the year with $490.5 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations into the second half of 2029, reflecting a degree of financial stability.
- Operational Assurance: Despite the disappointing Q4 results, the substantial cash reserves provide a buffer for future R&D and operations, potentially aiding long-term growth in the biopharmaceutical sector.
- Market Reaction Outlook: Given the earnings miss, the stock price may face short-term pressure, prompting investors to monitor the company's strategic adjustments and market performance closely.
See More
Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results
- Positive Study Results: Xenon Pharmaceuticals announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures, with a placebo-adjusted median percentage change of -42.7% in the 25 mg group, significantly outperforming the previous Phase 2b study results.
- Primary Endpoint Achieved: The study met its primary endpoint, with 54.8% of participants in the 25 mg group achieving at least a 50% reduction in monthly seizure frequency compared to 20.8% in the placebo group, demonstrating the efficacy of azetukalner.
- Future Application Plans: Xenon plans to submit a New Drug Application (NDA) to the FDA in Q3 2026, and if approved, azetukalner will be the only KV7 potassium channel opener available for epilepsy treatment, potentially transforming the treatment landscape for patients with uncontrolled seizures.
- Positive Market Reaction: Xenon shares rose 16.17% to $48.72 in premarket trading on Monday, reflecting strong investor response to the study results, while analysts maintain a Buy rating with an average price target of $56.78.
See More
Rapport Therapeutics Q1 Financial Results Analysis
- Financial Performance: Rapport Therapeutics reported a Q1 GAAP EPS of -$0.42 with revenue of only $0.02 million, indicating significant challenges in revenue growth that may impact investor confidence.
- Cash Position: As of March 31, 2026, the company had $476.8 million in cash, cash equivalents, and short-term investments, down from $490.5 million as of December 31, 2025, reflecting pressure on the company's financial management.
- Cash Runway: The company expects its current cash and short-term investments to fund operating expenses and capital expenditures into the second half of 2029, although it faces challenges with low revenue, necessitating careful monitoring of cash utilization.
- Market Outlook: Rapport Therapeutics' presentation at the Stifel 2026 Virtual CNS Forum could influence its future financing capabilities, prompting investors to closely watch its subsequent financial performance and market reactions.
See More
Third Rock Ventures Sells Shares in Rapport Therapeutics
- Transaction Overview: Third Rock Ventures V, L.P. sold 426,005 shares of Rapport Therapeutics in an open-market transaction valued at approximately $17.18 million, reducing its ownership stake by 5.3% while still holding 6.7 million shares directly, indicating continued confidence in the company's prospects.
- Transaction Context: The sale was executed under a Rule 10b5-1 trading plan, suggesting it was a pre-scheduled liquidity event rather than discretionary selling, reflecting the management's strategic planning and market timing.
- Market Performance Impact: Following a 230% increase in Rapport Therapeutics' stock price over the past year, this divestment does not alter Third Rock's fundamental view on the company but rather appears to be a strategy to realize some gains while maintaining significant exposure to future growth.
- R&D Progress and Outlook: Rapport recently reported a 90% median reduction in clinical seizures for its RAP-219 Phase 2 trial, establishing a solid foundation for future drug development, with two Phase 3 trials expected to commence in the second quarter, further enhancing the company's growth potential.
See More
Rapport Therapeutics' RAP-219 Shows Significant Seizure Reduction in Epilepsy Patients
- Significant Clinical Efficacy: Rapport Therapeutics' RAP-219 achieved a 90% median reduction in seizures during the first four weeks of follow-up after an eight-week treatment, indicating its clinical significance and potential market value in treating epilepsy.
- Robust Study Results: In a study involving 30 adults with drug-resistant focal onset seizures, RAP-219's long half-life of approximately 22 days allowed for a 90% median reduction in seizures during weeks 9-12 post-treatment, with a sustained 59% reduction in weeks 13-16, demonstrating its ability to maintain seizure control.
- Good Safety Profile: RAP-219 was generally well tolerated with only mild treatment-related side effects reported; serious adverse events occurred but were deemed unrelated to the drug by investigators, enhancing its feasibility for clinical use.
- Future Development Plans: Rapport plans to initiate two pivotal Phase 3 trials, FOCUS 1 and FOCUS 2, in the second quarter of 2026 to further evaluate RAP-219 for focal onset seizures, while also conducting a Phase 2 trial for bipolar mania, showcasing the company's broad strategy in neurological disorders.
See More
Form 144: Rapport Therapeutics (RAPP.US) 10% Stakeholder Plans to Sell $17.18 Million in Common Shares
- Stock Sale Announcement: Third Rock Ventures, L.P. plans to sell 426,001 shares of its common stock on April 17, 2023.
- Market Value: The total market value of the shares being sold is approximately $17.18 million.
See More
Rapport Therapeutics Reports Q4 Earnings Miss
- Earnings Miss: Rapport Therapeutics reported a Q4 GAAP EPS of -$0.72, missing expectations by $0.03, indicating challenges in profitability that could impact investor confidence.
- Cash Position: The company ended the year with $490.5 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations into the second half of 2029, reflecting a degree of financial stability.
- Operational Assurance: Despite the disappointing Q4 results, the substantial cash reserves provide a buffer for future R&D and operations, potentially aiding long-term growth in the biopharmaceutical sector.
- Market Reaction Outlook: Given the earnings miss, the stock price may face short-term pressure, prompting investors to monitor the company's strategic adjustments and market performance closely.
See More
Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results
- Positive Study Results: Xenon Pharmaceuticals announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures, with a placebo-adjusted median percentage change of -42.7% in the 25 mg group, significantly outperforming the previous Phase 2b study results.
- Primary Endpoint Achieved: The study met its primary endpoint, with 54.8% of participants in the 25 mg group achieving at least a 50% reduction in monthly seizure frequency compared to 20.8% in the placebo group, demonstrating the efficacy of azetukalner.
- Future Application Plans: Xenon plans to submit a New Drug Application (NDA) to the FDA in Q3 2026, and if approved, azetukalner will be the only KV7 potassium channel opener available for epilepsy treatment, potentially transforming the treatment landscape for patients with uncontrolled seizures.
- Positive Market Reaction: Xenon shares rose 16.17% to $48.72 in premarket trading on Monday, reflecting strong investor response to the study results, while analysts maintain a Buy rating with an average price target of $56.78.
See More
